Unique ID issued by UMIN | UMIN000041509 |
---|---|
Receipt number | R000047388 |
Scientific Title | A phase II neoadjuvant trial of sequential nab-paclitaxel followed by dose dense epirubicine/cyclophosphamide (ddEC) in operable breast cancer |
Date of disclosure of the study information | 2020/09/01 |
Last modified on | 2020/08/21 19:06:57 |
A phase II neoadjuvant trial of sequential nab-paclitaxel followed by dose dense epirubicine/cyclophosphamide (ddEC) in operable breast cancer
A phase II neoadjuvant trial of sequential nab-paclitaxel followed by ddEC in operable breast cancer
A phase II neoadjuvant trial of sequential nab-paclitaxel followed by dose dense epirubicine/cyclophosphamide (ddEC) in operable breast cancer
A phase II neoadjuvant trial of sequential nab-paclitaxel followed by ddEC in operable breast cancer
Japan |
breast cancer
Breast surgery |
Malignancy
NO
To evaluate the efficacy and safety of neoadjuvant chemotherapy of sequential nab-paclitaxel followed by dose dense epirubicine/cyclophosphamide (ddEC) in operable breast cancer
Safety,Efficacy
Phase II
Pathological complete response (pCR) in breast and axillary lymph node
Adverse events with nab-paclitaxel and ddEC therapy
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine |
neoadjuvant sequential 4cycle nab-paclitaxel tri-weekly, with trastuzumab, pertuzumab in HER2-positive patients, followed by 4 cycle dose dense epirubicine/cyclophosphamide (ddEC) tri-weekly
nab-paclitaxel 4cycle
nab-paclitaxel 260mg/m2, day1, q3w
HER2-positive disease, trastuzumab 8mg/kg,
6mg/kg and pertuzumab 840mg, 420mg on day1 of subsequent cycles with nab-paclitaxel
ddEC 4cycle
Epirubicin 90mg/m2, Cyclophosphamide 600mg/m2, day 1, q2w
20 | years-old | <= |
75 | years-old | >= |
Female
1)Histologically confirmed operable breast c ancer
2)Clinical stage 1, 2, 3
3)Operable breast cancer in neoadjuvant setting
4)Over 20 year-old, under 75 year-old female
5)Previously untreated by operation, radiotherapy, chemotherapy, endocrine therapy
6)Exhibited adequate organ function
7)Performance status(PS) 0-1
8)Signed written informed consent
1)Known hypersensitivity to human serum alb umin
2)Concurrent, serious or uncontrolled infect ions
3)Inadequately controlled or serious history of cardiac disease
4)Confirmed symptomatic brain metastasis
5)Current pregnancy and lactation, or possib ility of pregnancy
6)Known drug allergy to any of study drugs
7)Assessment by investigator that subject un able to comply with protocol
20
1st name | Yutaka |
Middle name | |
Last name | Mizuno |
Yokkaichi Municipal Hospital
Breast Surgery
510-8567
2-2-37 Shibata Yokkaichi-city Mie
059-354-1111
mizunoy729@yokkaichihp01.jp
1st name | Yutaka |
Middle name | |
Last name | Mizuno |
Yokkaichi Municipal Hospital
Breast Surgery
510-8567
2-2-37 Shibata Yokkaichi-city Mie
059-354-1111
mizunoy729@yokkaichihp01.jp
Breast Surgery, Yokkaichi Municipal Hospital
Breast Surgery, Yokkaichi Municipal Hospital
Other
Institutional Review Board, Yokkaichi Municipal Hospital
2-2-37 Shibata Yokkaichi-city Mie
059-354-1111
chiken@yokkaichihp01.jp
NO
市立四日市病院(三重県)
2020 | Year | 09 | Month | 01 | Day |
Unpublished
Open public recruiting
2020 | Year | 04 | Month | 16 | Day |
2020 | Year | 07 | Month | 16 | Day |
2020 | Year | 07 | Month | 17 | Day |
2025 | Year | 12 | Month | 31 | Day |
2020 | Year | 08 | Month | 21 | Day |
2020 | Year | 08 | Month | 21 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047388